• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

anti-TNFSF11 antibody :: Mouse anti-Human TNFSF11 Monoclonal Antibody

Scan QR to view Datasheet
Catalog # MBS690279
Unit / Price
  0.1 mg  /  $490 +1 FREE 8GB USB
anti-TNFSF11 antibody
Product Name

TNFSF11, Monoclonal Antibody

Popular Item
Also Known As

Mouse Anti-Human TNFSF11

Product Synonym Names
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Immunogen Sequence Length
Chromosome Location
Chromosome: 13; NC_000013.11 (42562736..42608013). Location: 13q14
3D Structure
ModBase 3D Structure for O14788
Clone Number
Species Reactivity
protein G chromatography
Antibody Generation
This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse) immunized with Human TNFSF11 recombinant protein (also called TRANCE).
Human recobinant TNFSF11
Reconstitute the antibody with 200 ul sterile PBS and the final concentration is 500 ug/ml.
This antibody was selected for its ability to detect human TNFSF11.
Preparation and Storage
Lyophilized samples are stable for 2 years from date of receipt when stored at -70 degree C. Reconstituted antibody can be aliquoted and stored frozen at < -20 degree C for at least for six months without detectable loss of activity.
ISO Certification
Manufactured in an ISO 9001:2015 Certified Laboratory.
Other Notes
Small volumes of anti-TNFSF11 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-TNFSF11 antibody
TNF-related activation-induced cytokines (TRANCE), also called RANK Ligand (RANKL, receptor activator of NF-kB ligand), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is a member of the TNF superfamily. Mouse and human TRANCE share 85% amino acid sequence identity. TRANCE is primarily expressed in T cells and T cell rich organs, such as thymus and lymph nodes.
Applications Tested/Suitable for anti-TNFSF11 antibody
Western Blot (WB), Immunohistochemistry (IHC) - Paraffin, Flow Cytometry (FC/FACS)
Application Notes for anti-TNFSF11 antibody
IHC (paraffin): 1:20-1:100
WB: Use at 1:500-1000
Neutralization of TNFSF11 bioactivity: Yes
NCBI/Uniprot data below describe general gene information for TNFSF11. It may not necessarily be applicable to this product.
NCBI Accession #
NCBI GenBank Nucleotide #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
35,478 Da
NCBI Official Full Name
tumor necrosis factor ligand superfamily member 11 isoform 1
NCBI Official Synonym Full Names
tumor necrosis factor (ligand) superfamily, member 11
NCBI Official Symbol
TNFSF11  [Similar Products]
NCBI Official Synonym Symbols
  [Similar Products]
NCBI Protein Information
tumor necrosis factor ligand superfamily member 11; osteoprotegerin ligand; osteoclast differentiation factor; TNF-related activation-induced cytokine; receptor activator of nuclear factor kappa B ligand; receptor activator of nuclear factor kappa-B ligand
UniProt Protein Name
Tumor necrosis factor ligand superfamily member 11
UniProt Synonym Protein Names
Osteoclast differentiation factor; ODF; Osteoprotegerin ligand; OPGL; Receptor activator of nuclear factor kappa-B ligand; RANKL; TNF-related activation-induced cytokine
UniProt Gene Name
TNFSF11  [Similar Products]
UniProt Synonym Gene Names
UniProt Entry Name
NCBI Summary for TNFSF11
This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found. [provided by RefSeq, Jul 2008]
UniProt Comments for TNFSF11
Function: Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. Ref.7

Subunit structure: Homotrimer

Probable. Interacts with TNFRSF11B. Ref.7

Subcellular location: Isoform 1: Cell membrane; Single-pass type II membrane protein. Isoform 3: Cell membrane; Single-pass type II membrane protein. Isoform 2: Cytoplasm

By similarity. Tumor necrosis factor ligand superfamily member 11, soluble form: Secreted

By similarity.

Tissue specificity: Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid.

Induction: Up-regulated by T-cell receptor stimulation.

Post-translational modification: The soluble form of isoform 1 derives from the membrane form by proteolytic processing

By similarity. The cleavage may be catalyzed by ADAM17.

Involvement in disease: Osteopetrosis, autosomal recessive 2 (OPTB2) [MIM:259710]: A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.8

Sequence similarities: Belongs to the tumor necrosis factor family.
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

Contact Us

Please fill out the form below and our representative will get back to you shortly.